The biopharma TFF Pharmaceuticals (NSDQ:TFFP) has announced that its inhalation powder of the immunosuppressive drug tacrolimus was well tolerated in a Phase 1 trial in lung transplant patients.
Tacrolimus is a traditional option for preventing rejection of a transplanted organ, albeit in tablet or capsule form.
It is common for lung transplant recipients to have high tacrolimus blood concentrations. Such concentrations are linked to an elevated risk of acute kidney injury and, potentially, chronic kidney disease. To minimize the risk of injury, physicians rely on therapeutic drug monitoring to maintain consistent drug levels in a narrow window.
TFF Pharmaceuticals believes that inhalable tacrolimus can potentially address the problem by maintaining high levels of the drug at the graft site rather than systemically.
TFF plans to conduct a Phase 2 study of the powdered tacrolimus in lung transplant recipients.
“The data from this Phase 1 stu…